Spectrophotometric determinations of most commonly used statins in pharmaceutical preparations with 2,3-dichloro-5,6-dicyanobenzoquinone

Year 2020, Volume: 50 Issue: 2, 95 - 102, 27.08.2020

Gamze Ergin Kızılçay Sıdıka Ertürk Toker

Abstract

Background and Aims: In this study, simple, accurate and precise spectrophotometric methods were developed for the determination of five 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitors in pure and pharmaceutical dosage forms. Methods: In the developed methods, atorvastatin fluvastatin, pitavastatin, rosuvastatin and simvastatin were used in this class of drugs called statins. The methods were based on the charge-transfer reaction of n-electron donor drugs with π-acceptor 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). All variables such as temperature, time, reaction medium, amount of reagent were examined for optimal formation of complexes to be given by the drugs with DDQ and optimal conditions were determined. Results: The linearity ranges for atorvastatin, fluvastatin, pitavastatin, rosuvastatin and simvastatin were found to be 0.5-50, 1-6, 2.5-50, 5-25 and 5-50 μg/mL, respectively. Conclusion: The proposed methods were successfully applied to both the pure and the pharmaceutical dosage forms

Keywords

HMG-CoA reductase inhibitors, spectrophotometric determination, charge-transfer reaction, DDQ, pharmaceutical preparations

References

• Abdallah, O. M. (2011). RP-HPLC determination of three anti-hyperlipidemic drugs in spiked human plasma and dosage forms. E-Journal of Chemistry, 8, 753–761.
• Abdel-Gawad, F. M., Issa, Y. M., Fahmy, H. M., & Hussein, H. M. (1998). Spectrophotometric determination of ciprofloxacin in pure form and in tablets through charge-transfer complexation reactions. Microchimica Acta, 130, 35–40.
• Abdellatef, H. E. (1998). Utility of certain π-acceptors for the spectrophotometric determination of perindopril. Journal of Pharmaceutical and Biomedical Analysis, 17, 1267–1271.
• Antal, I., Koneracka, M., Zavisova, V., Kubovcikova, M., Kormosh, Zh., & Kopcansky, P. (2017). Statins determination: A review of electrochemical techniques. Critical Reviews in Analytical Chemistry, 47, 474–489.
• Ashour, S., Bahbouh, M., & Khateeb, M. (2010). Kinetic spectrophotometric determination of fluvastatin in pharmaceutical preparations. International Journal of Biomedical Science, 6, 19–26.
• Carlucci, G., Mazzeo, P., Biordi, L., & Bologna, M. (1992). Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high performance liquid chromatography with UV detection. Journal of Pharmaceutical and Biomedical Analysis, 10, 693–697.
• Caslake, M. J., Stewart, G., Day, S. P., Daly, E., McTaggart, F., Chapman, M. J. … Packard, C. J. (2003). Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis, 171, 245–253.
• Erk, N. (2002). Rapid spectrophotometric method for quantitative determination of simvastatin and fluvastatin in human serum and pharmaceutical formulations. Phamazie, 57, 817–819.
• Foster, R. (1969). Organic charge-transfer complexes. London, UK: Academic Press.
• Gomes, F., Garcia, P., Alves, J., Singh, A., Kedor-Hackmann, E., & Santoro, M. (2009). Development and validation of stability – indicating HPLC methods for quantitative determination of pravastatin, fluvastatin, atorvastatin and rosuvastatin in pharmaceuticals. Analytical Letters, 42, 1784–1804.
• Gupta, A., Mishra, P., & Shah, K. (2009). Simple UV spectrophotometric determination of rosuvastatin calcium in pure form and in pharmaceutical formulations. E-Journal of Chemistry, 6, 89–92.
• Hussein, S. A., Mohamed, A. M. I., & Abdel-Alim, A. A. M. (1989). Utility of certain π-acceptors for the spectrophotometric determination of gliclazide and tolazamide. Analyst, 114, 1129–1131.
• International Conference on Harmonization. (2005). ICH Q2 (R1) harmonised tripartite guideline, validation of analytical procedures: Text and methodology. Geneva. • Job, P. (1928). Formation and stability of inorganic complexes in solution. Annales de Chimie, 9, 113–203.
• Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E. … STELLAR Study Group. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). The American Journal of Cardiology, 92, 152–160.
• Kaila, H. O., Ambasana, M. A., Thakkar, R. S., Saravaia, H. T., & Shah, A. K. (2010). A new improved RP-HPLC method for assay of rosuvastatin calcium in tablets. Indian Journal of Pharmaceutical Sciences, 72, 592–598.
• Kokilambigai, K. S., Seetharaman, R., & Lakshmi, K.S. (2017). Critical review on the analytical techniques for the determination of the oldest statin-atorvastatin-in bulk, pharmaceutical formulations and biological fluids. Critical Reviews in Analytical Chemistry, 47, 538–555.
• Kovar, K. A., & Abdel-Hamid, M. E. (1984). Charge-transfer complexes 2. molecular-complexes and radicals of drugs containing the imidazoline ring. Archiv der Pharmazie, 317, 246–250.
• Kovar, K. A., Mayer, W., & Auterhoff, H. (1981). Molecular complexes and radicals of procaine. Archiv der Pharmazie, 314, 447–458.
• Krishna, M.V., & Sankar, D. G. (2007). Adaptation of color reactions for spectrophotometric determination of pitavastatin calcium in bulk drugs and in pharmaceutical formulations. E-Journal of Chemistry, 4, 272–278.
• Kumar, N. S., Nisha, N., Nirmal, J., Sonali, N., & Bagyalakshmi, J. (2011). HPLC determination of pitavastatin calcium in pharmaceutical dosage forms. Pharmaceutica Analytica Acta, 2, 1–4.
• Lennernas, H., & Fager, G. (1997). Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 32, 403–425.
• Melby, L. R., & Patai, S. (1970). The Chemistry of the Cyano Group. New York: Interscience.
• Moussa, B. A., Mohamed, M. F., & Youssef, N. F. (2010). Derivative spectrophotometric method for simultaneous determination of ezetimibe and simvastatin in combined tablets. European Journal of Chemistry, 1, 348–351.
• Ochiai, H., Uchiyama, N., Imagaki, K., Hata, S., & Kamei, T. (1997). Determination of simvastatin and its active metabolite in human plasma by column‐switching high performance liquid chromatography with fluorescence detection after derivatization with 1‐ bromoacetylpyrene. Journal of Chromatography B, 694, 211–217.
• Rao, C. N.R., Bhat, S. N., & Dwivedi, P. C. (1972). Applied Spectroscopy Reviews 5. New York, NY: Brame E.D.
• Saleh, G. A. (1998). Charge-transfer complexes of barbiturates and phenytoin. Talanta, 46, 111–121.
• Saleh, G. A., Askal, H. F., Darwish, L. A., & El-Shorbagi, A. N. (2003). Spectroscopic analytical study for the charge-transfer complexation of certain cephalosporins with chloranilic acid. Analytical Sciences, 19, 281–287.
• Saminathan, J., Sankar, A. S. K., Anandakumar, K., & Vetrichelvan, T. (2009). Simple UV spectrophotometric method for the determination of fluvastatin sodium in bulk and pharmaceutical formulations. E-Journal of Chemistry, 6, 1233–1239.
• Sane, R. T., Kamat, S. S., Menon, S. N., Inamdar, S. R., & Mote, M. R. (2007). Determination of rosuvastatin calcium in its bulk drug and pharmaceutical preparations by highperformance thin-layer chromatography. JPC Journal of Planar Chromatography -Modern TLC, 18, 194–198.
• Sankar, G. D., Babu, J. P., Kumar, A. B., & Krishna, V. M. (2007). RPHPLC method for the estimation of Lomitapide calcium in bulk and pharmaceutical dosage form. Acta Ciencia Indica, Series Chemistry, 33,1–4.
• Stanisz, B., & Rafa, W. (2008). Development and validation of UV derivative spectrophotometric method for determination of atorvastatin in tablets. Chemia Analityczna-Warsaw, 53, 417–428.
• Sweetman, S.C. (2005). Martindale the complete drug reference. United Kingdom:34th Ed., Royal Pharmaceutical Society of Great Britain.
• Terata, Y., Saito, T., Fujiwara, Y., Hasegawa, H., Miura, H., Watanabe, H. … Miura, M. (2003). Pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis. Pharmacology, 68, 169–176.
• Tobert, J. A. (2003). Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery, 2, 517–526.
• United States Pharmacopoeia Convention Inc. (2007). United States Pharmacopoeia National Formulary, USP 30-NF 25. Rockville, Maryland, USA.
• United States Pharmacopoeia Convention Inc. (2009). United States Pharmacopoeia National Formulary, USP 32-NF 27. Rockville, Maryland, USA.
• Vuletic, M., Cindric, M., & Kouznjak, J. D. (2005). Identification of unknown impurities of atorvastatin calcium substances and tablets by liquid chromatography/ tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 37, 715–721.
• Wang, L., & Asgharnejad, M. (2000). Second-derivative UV spectrometric determination of simvastatin in its tablet dosage form. Journal of Pharmaceutical and Biomedical Analysis, 21, 1243–1248.
• Yadav, S., Mhaske, D. V., Kakad, A. B., Patil, B. D., Kadam, S. S., & Dhaneshwar, S. R. (2005). A simple and sensitive HPTLC method for determination of content uniformity of atorvastatin calcium tablet. Indian Journal of Pharmaceutical Sciences, 67, 182–186.